Meghan Delaney1, Paul C Stark, Minhyung Suh, Darrell J Triulzi, John R Hess, Marie E Steiner, Christopher P Stowell, Steven R Sloan. 1. From the *Medical Division and Department of Laboratory Medicine, University of Washington, Seattle, Washington; †Center for Epidemiological and Statistical Research, New England Research Institutes (Data Coordinating Center), Watertown, Massachusetts; ‡Division of Transfusion Medicine, Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania; §Harborview Medical Center, Department of Laboratory Medicine and Division of Hematology, University of Washington, Seattle, Washington; ‖Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; ¶Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and #Department of Laboratory Medicine, Boston Children's Hospital and Department of Pathology, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Cardiac surgery is the most common setting for massive transfusion in medically advanced countries. Studies of massive transfusion after injury suggest that the ratios of administered plasma and platelets (PLT) to red blood cells (RBCs) affect mortality. Data from the Red Cell Storage Duration Study (RECESS), a large randomized trial of the effect of RBC storage duration in patients undergoing complex cardiac surgery, were analyzed retrospectively to investigate the association between blood component ratios used in massively transfused patients and subsequent clinical outcomes. METHODS: Massive transfusion was defined as those who had ≥6 RBC units or ≥8 total blood components. For plasma, high ratio was defined as ≥1 plasma unit:1 RBC unit. For PLT transfusion, high ratio was defined as ≥0.2 PLT doses:1 RBC unit; PLT dose was defined as 1 apheresis PLT or 5 whole blood PLT equivalents. The clinical outcomes analyzed were mortality and the change in the Multiple Organ Dysfunction Score (ΔMODS) comparing the preoperative score with the highest composite score through the earliest of death, discharge, or day 7. Outcomes were compared between patients transfused with high and low ratios. Linear and Cox regression were used to explore relationships between predictors and continuous outcomes and time to event outcomes. RESULTS: A total of 324 subjects met the definition of massive transfusion. In those receiving high plasma:RBC ratio, the mean (SE) 7- and 28-day ΔMODS was 1.24 (0.45) and 1.26 (0.56) points lower, (P = .007 and P = .024), respectively, than in patients receiving lower ratios. In patients receiving high PLT:RBC ratio, the mean (SE) 7- and 28-day ΔMODS were 1.55 (0.53) and 1.49 (0.65) points lower (P = .004 and P = .022), respectively. Subjects who received low-ratio plasma:RBC transfusion had excess 7-day mortality compared with those who received high ratio (7.2% vs 1.7%, respectively, P = .0318), which remained significant at 28 days (P = .035). The ratio of PLT:RBCs was not associated with differences in mortality. CONCLUSIONS: This analysis found that in complex cardiac surgery patients who received massive transfusion, there was an association between the composition of blood products used and clinical outcomes. Specifically, there was less organ dysfunction in those who received high-ratio transfusions (plasma:RBCs and PLT:RBCs), and lower mortality in those who received high-ratio plasma:RBC transfusions.
BACKGROUND: Cardiac surgery is the most common setting for massive transfusion in medically advanced countries. Studies of massive transfusion after injury suggest that the ratios of administered plasma and platelets (PLT) to red blood cells (RBCs) affect mortality. Data from the Red Cell Storage Duration Study (RECESS), a large randomized trial of the effect of RBC storage duration in patients undergoing complex cardiac surgery, were analyzed retrospectively to investigate the association between blood component ratios used in massively transfused patients and subsequent clinical outcomes. METHODS: Massive transfusion was defined as those who had ≥6 RBC units or ≥8 total blood components. For plasma, high ratio was defined as ≥1 plasma unit:1 RBC unit. For PLT transfusion, high ratio was defined as ≥0.2 PLT doses:1 RBC unit; PLT dose was defined as 1 apheresis PLT or 5 whole blood PLT equivalents. The clinical outcomes analyzed were mortality and the change in the Multiple Organ Dysfunction Score (ΔMODS) comparing the preoperative score with the highest composite score through the earliest of death, discharge, or day 7. Outcomes were compared between patients transfused with high and low ratios. Linear and Cox regression were used to explore relationships between predictors and continuous outcomes and time to event outcomes. RESULTS: A total of 324 subjects met the definition of massive transfusion. In those receiving high plasma:RBC ratio, the mean (SE) 7- and 28-day ΔMODS was 1.24 (0.45) and 1.26 (0.56) points lower, (P = .007 and P = .024), respectively, than in patients receiving lower ratios. In patients receiving high PLT:RBC ratio, the mean (SE) 7- and 28-day ΔMODS were 1.55 (0.53) and 1.49 (0.65) points lower (P = .004 and P = .022), respectively. Subjects who received low-ratio plasma:RBC transfusion had excess 7-day mortality compared with those who received high ratio (7.2% vs 1.7%, respectively, P = .0318), which remained significant at 28 days (P = .035). The ratio of PLT:RBCs was not associated with differences in mortality. CONCLUSIONS: This analysis found that in complex cardiac surgery patients who received massive transfusion, there was an association between the composition of blood products used and clinical outcomes. Specifically, there was less organ dysfunction in those who received high-ratio transfusions (plasma:RBCs and PLT:RBCs), and lower mortality in those who received high-ratio plasma:RBC transfusions.
Authors: John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle Journal: JAMA Date: 2015-02-03 Impact factor: 56.272
Authors: P C Hébert; E Yetisir; C Martin; M A Blajchman; G Wells; J Marshall; M Tweeddale; G Pagliarello; I Schweitzer Journal: Crit Care Med Date: 2001-02 Impact factor: 7.598
Authors: Marie E Steiner; Paul M Ness; Susan F Assmann; Darrell J Triulzi; Steven R Sloan; Meghan Delaney; Suzanne Granger; Elliott Bennett-Guerrero; Morris A Blajchman; Vincent Scavo; Jeffrey L Carson; Jerrold H Levy; Glenn Whitman; Pamela D'Andrea; Shelley Pulkrabek; Thomas L Ortel; Larissa Bornikova; Thomas Raife; Kathleen E Puca; Richard M Kaufman; Gregory A Nuttall; Pampee P Young; Samuel Youssef; Richard Engelman; Philip E Greilich; Ronald Miles; Cassandra D Josephson; Arthur Bracey; Rhonda Cooke; Jeffrey McCullough; Robert Hunsaker; Lynne Uhl; Janice G McFarland; Yara Park; Melissa M Cushing; Charles T Klodell; Ravindra Karanam; Pamela R Roberts; Cornelius Dyke; Eldad A Hod; Christopher P Stowell Journal: N Engl J Med Date: 2015-04-09 Impact factor: 91.245
Authors: John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar Journal: JAMA Surg Date: 2013-02 Impact factor: 14.766
Authors: Jeffrey P Jacobs; David M Shahian; Richard L Prager; Fred H Edwards; Donna McDonald; Jane M Han; Richard S D'Agostino; Marshall L Jacobs; Benjamin D Kozower; Vinay Badhwar; Vinod H Thourani; Henning A Gaissert; Felix G Fernandez; Cam Wright; James I Fann; Gaetano Paone; Juan A Sanchez; Joseph C Cleveland; J Matthew Brennan; Rachel S Dokholyan; Sean M O'Brien; Eric D Peterson; Frederick L Grover; G Alexander Patterson Journal: Ann Thorac Surg Date: 2015-10-31 Impact factor: 4.330
Authors: Walter Sunny Dzik; Alyssa Ziman; Claudia Cohn; Menaka Pai; Miguel Lozano; Richard M Kaufman; Meghan Delaney; Kathleen Selleng; Michael F Murphy; Tor Hervig; Mark Yazer Journal: Transfusion Date: 2015-10-09 Impact factor: 3.157
Authors: A J Zatta; Z K McQuilten; B Mitra; D J Roxby; R Sinha; S Whitehead; S Dunkley; S Kelleher; C Hurn; P A Cameron; J P Isbister; E M Wood; L E Phillips Journal: Vox Sang Date: 2014-04-02 Impact factor: 2.144
Authors: Simon J Stanworth; Timothy P Morris; Christine Gaarder; J Carel Goslings; Marc Maegele; Mitchell J Cohen; Thomas C König; Ross A Davenport; Jean-Francois Pittet; Pär I Johansson; Shubha Allard; Tony Johnson; Karim Brohi Journal: Crit Care Date: 2010-12-30 Impact factor: 9.097
Authors: Alexander P J Vlaar; Joanna C Dionne; Sanne de Bruin; Marije Wijnberge; S Jorinde Raasveld; Frank E H P van Baarle; Massimo Antonelli; Cecile Aubron; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella C A Müller; Marcus Lance; Nathan D Nielsen; Herbert Schöchl; Beverley J Hunt; Maurizio Cecconi; Simon Oczkowski Journal: Intensive Care Med Date: 2021-10-22 Impact factor: 17.440
Authors: Matthew A Warner; Ryan D Frank; Timothy J Weister; Nageswar R Madde; Ognjen Gajic; Daryl J Kor Journal: Anesth Analg Date: 2020-08 Impact factor: 6.627
Authors: Dou Huang; Changwei Chen; Yue Ming; Jing Liu; Li Zhou; Fengjiang Zhang; Min Yan; Lei Du Journal: Medicine (Baltimore) Date: 2019-02 Impact factor: 1.817